Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip™ Passes Animal Study
01 Julio 2024 - 4:30AM
Business Wire
VClip™ restores mitral valve function and
overcomes limitations of current technologies
Anteris Technologies Ltd (ASX: AVR), a structural heart company
developing DurAVR™ THV, a new class of TAVR and the world’s only
balloon-expandable, single-piece biomimetic aortic replacement
valve shaped to mimic the native human valve, and v2vmedtech, inc.,
a structural heart company developing a next generation
Transcatheter Edge to Edge Repair (TEER) system for mitral and
tricuspid valve regurgitation today announced they have reached
concept lock on the first phase of the system.
TEER is fast becoming the primary intervention for patients with
mitral and tricuspid valve disease, however current marketed
systems have limitations that often prevent optimal procedural
outcomes or limit eligibility for certain patient groups. The
VClipTM design intent is to address these unmet needs and provide
better outcomes for patients.
Dr. Vinayak Bapat, CMO v2vmedtech, inc., commented, “Today’s
concept lock provides us important proof of concept data. Working
closely with engineers and leading interventional cardiologists has
allowed us to proceed rapidly as we drive innovation in the TEER
space.”
David St Denis, CEO v2vmedtech, inc. and COO Anteris
Technologies Ltd, commented, “Achieving this milestone is an
important step as we advance VClipTM toward a first-in-human study.
Applying the same physician led collaborative design model as we
successfully deployed in the development of DurAVRTM has allowed us
to make significant progress in a rapid manner.”
About Anteris Technologies Ltd (ASX: AVR)
Anteris Technologies Ltd (ASX: AVR) is a structural heart
company committed to designing, developing, and commercialising
innovative medical devices. Founded in Australia, with a
significant presence in Minneapolis, USA (a MedTech hub), Anteris
is science-driven, with an experienced team of multidisciplinary
professionals delivering transformative solutions to structural
heart disease patients.
The Company’s lead product, DurAVRTM, is a transcatheter heart
valve (THV) for treating aortic stenosis. DurAVRTM THV was designed
in partnership with the world’s leading interventional
cardiologists and cardiac surgeons. It is the first transcatheter
aortic valve replacement (TAVR) to use a single piece of
bioengineered tissue. This biomimetic valve is uniquely shaped to
mimic the performance of a healthy human aortic valve.
DurAVRTM THV is made using ADAPT® tissue, Anteris’ patented
anti-calcification tissue technology. ADAPT® tissue has been used
clinically for over 10 years and distributed for use in over 55,000
patients worldwide.
The ComASURTM Delivery System was designed to provide controlled
deployment and accurate placement of the DurAVRTM THV with
balloon-expandable delivery, allowing precise alignment with the
heart’s native commissures to achieve optimal valve
positioning.
Anteris Technologies is set to revolutionize the structural
heart market by delivering clinically superior solutions for
significant unmet clinical needs.
Authorisation and Additional information
This announcement was authorised by the Board of Directors.
Website
www.anteristech.com
Twitter
@AnterisTech
Facebook
www.facebook.com/AnterisTechnologies
LinkedIn
https://www.linkedin.com/company/anteristech
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240701929582/en/
For more information:
Investor Relations investors@anteristech.com Anteris
Technologies Ltd +61 1300 550 310 | +61 7 3152 3200
Investor Relations (US) Malini Chatterjee, PhD. Managing
Director Blueprint Life Science Group +1 917 330 4269
Avaron Mining (TSXV:AVR)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Avaron Mining (TSXV:AVR)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024